Literature DB >> 3706572

Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat.

E A Neuwelt, J Minna, E Frenkel, P A Barnett, C I McCormick.   

Abstract

Pharmacokinetic parameters of iodinated monoclonal antibody (MAb) delivery to normal rat brain were examined. The mean cerebrovascular permeability-surface area (PA; permeability X capillary surface area) to immunoglobulin M (IgM) MAb (mol wt 1,000,000) 10 min after infusion was 0.40 X 10(-6) S-1. When osmotic blood-brain barrier (BBB) disruption is utilized, the PA increased to 8.36 X 10(-6) S-1. Neither intravenous nor intracarotid MAb administration significantly affected delivery to brain. However, osmotic BBB opening significantly (P less than 0.0005) increased MAb uptake independent of the route of administration. After BBB opening and intracarotid MAb the maximum concentration in brain at 1 h was 0.72% per gram of the total administered dose. For 6 h postdisruption, ipsilateral brain levels were 25- to 100-fold greater than in the contralateral hemisphere or nonbarrier-disrupted controls. MAb concentration in brain slightly decreased over 72 h (P less than 0.05). Antibody recovered from disrupted brain retained 90% of its immunological reactivity for at least 24 h. MAb delivery to ipsilateral brain after BBB disruption was linear over a dose of 0.5-5.0 micrograms IgM, whereas the percentage of the total administered dose remained unchanged. After osmotic treatment, barrier opening was maximal to MAb delivery for 1 min with delivery declining rapidly thereafter. The type of anesthesia used and the administration of a thyroid-blocking agent were found to affect brain MAb levels after BBB disruption.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3706572     DOI: 10.1152/ajpregu.1986.250.5.R875

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  Anti-dopamine antibodies: effects on behavior in an "open field," pain sensitivity, CNS monoamine content, and functional activity of immunocytes in C57Bl/6 mice.

Authors:  N A Trekova; L A Vetrilé; L A Basharova; O I Mikovskaya; T G Khlopushina
Journal:  Neurosci Behav Physiol       Date:  2001 Jan-Feb

2.  Anesthetic efficacy of combinations of 0.5 m mannitol and lidocaine with epinephrine in inferior alveolar nerve blocks: a prospective randomized, single-blind study.

Authors:  Ronald Wolf; Al Reader; Melissa Drum; John Nusstein; Mike Beck
Journal:  Anesth Prog       Date:  2011

3.  Influence of mannitol on the penetration of teicoplanin into infected CSF of experimental Staphylococcus aureus meningitis of rabbits.

Authors:  G Manquat; J P Stahl; I Pelloux; M Micoud
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

4.  Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption.

Authors:  Marie Blanchette; Luc Tremblay; Martin Lepage; David Fortin
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

5.  Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.

Authors:  John A Boockvar; Apostolos J Tsiouris; Christoph P Hofstetter; Ilhami Kovanlikaya; Sherese Fralin; Kartik Kesavabhotla; Stephen M Seedial; Susan C Pannullo; Theodore H Schwartz; Philip Stieg; Robert D Zimmerman; Jared Knopman; Ronald J Scheff; Paul Christos; Shankar Vallabhajosula; Howard A Riina
Journal:  J Neurosurg       Date:  2010-10-22       Impact factor: 5.115

Review 6.  Intracarotid delivery of drugs: the potential and the pitfalls.

Authors:  Shailendra Joshi; Phillip M Meyers; Eugene Ornstein
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

7.  Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).

Authors:  Hans Christian Cederberg Helms; Mie Kristensen; Lasse Saaby; Gert Fricker; Birger Brodin
Journal:  Handb Exp Pharmacol       Date:  2022

8.  Real-time monitoring of human blood-brain barrier disruption.

Authors:  Vesa Kiviniemi; Vesa Korhonen; Jukka Kortelainen; Seppo Rytky; Tuija Keinänen; Timo Tuovinen; Matti Isokangas; Eila Sonkajärvi; Topi Siniluoto; Juha Nikkinen; Seppo Alahuhta; Osmo Tervonen; Taina Turpeenniemi-Hujanen; Teemu Myllylä; Outi Kuittinen; Juha Voipio
Journal:  PLoS One       Date:  2017-03-20       Impact factor: 3.240

9.  Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer.

Authors:  Tori B Terrell-Hall; Mohamed Ismail Nounou; Fatema El-Amrawy; Jessica I G Griffith; Paul R Lockman
Journal:  Oncotarget       Date:  2017-07-26

10.  Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis.

Authors:  Lorna Hayden; Tiia Semenoff; Verena Schultz; Simon F Merz; Katie J Chapple; Moses Rodriguez; Arthur E Warrington; Xiaohong Shi; Clive S McKimmie; Julia M Edgar; Katja Thümmler; Chris Linington; Marieke Pingen
Journal:  Acta Neuropathol Commun       Date:  2020-08-13       Impact factor: 7.801

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.